INTRODUCTION AND OBJECTIVES:
There remains lack of agreement on the optimal mpMRI prostate cancer scoring system with recent UK consensus recommending use of 5-point Likert assessment rather than PI-RADS. Using a paired cohort study design we compared clinical validity and utility of both scoring systems in the detection of clinically significant (cs) and insignificant (ci) prostate cancer (PCa).
METHODS: 329 pre-biopsy mpMRI scans in consecutive patients underwent prospective paired reporting using both Likert and PI-RADS (v2) by expert uro-radiologists. Patients were offered biopsy for any Likert or PI-RADS score !3; a score of 3 required PSAdensity !0.12ng/ml/ml. Utility was evaluated in terms of proportion biopsied, and proportion of csPCa and ciPCa detected. In those patients biopsied, overall accuracy of each system was assessed using receiver operating characteristic (ROC) curves. The primary threshold of csPCa was Gleason !3þ4; secondary thresholds of !Gleason 4þ3, Ahmed/UCL1 (Gleason !4þ3 or maximum cancer core length (CCL) !6 or total CCL !6) and Ahmed/UCL2 (Gleason !3þ4 or maximum CCL !4 or total CCL !6) were also used.
RESULTS: Median age was 66 (IQR: 13) and PSA was 8 (IQR: 6). A similar proportion of men met the biopsy threshold and underwent biopsy in both groups (69.3% vs. 75.7%). Likert predicted more csPCa than PI-RADS across all disease thresholds. Rates of ciPCa were comparable in each group (Table 1 ). ROC analysis of biopsied patients showed that, although both scoring systems performed well as predictors of csPCa, Likert exhibited higher areas under the curve (AUC) than PI-RADS across all thresholds (Table 2) .
CONCLUSIONS: Both scoring systems demonstrated good diagnostic performance. Overall, Likert was superior by all definitions of csPCa. It has the advantages of being flexible, intuitive and allows inclusion of clinical data. We recommend that its use be considered once radiologists have developed sufficient experience in reporting prostate mpMRI. METHODS: A prospectively maintained database of patient undergoing MRI followed by FBx for elevated PSA between 10/2014 and 07/2018 at our institution was reviewed. Patients with previously diagnosed PCa were excluded from the analysis. Time between MRI and FBx were evaluated as a continuous variable and as categorical variable as follows 5, 5-10, >10 weeks (w). Data were documented on a per lesion basis and each target in the MRI was classified for the level of suspicion of malignancy based on the Prostate Imaging-Reporting and Data System (PI-RADS). Generalized estimating equation models for correlated binary outcome data was fitted to assess the effect of time (or time intervals) between MRI and FBx on the histopathological findings in the defined MRI targets. Separated models were fitted for the detection of any cancer or Gleason 7 or higher PCa (Gleason 7 or greater) with adjustment for relevant characteristics.
Source of
RESULTS: A total 1,181 lesions from 806 men were analyzed. Prostate cancer was detected in 34.5% (407) of lesions, with 21.4% (253), 13% (154) and 65.5% (774) of lesions detecting clinically significant cancer (CSC), indolent (Gleason 6) PCa, or benign pathology, respectively. The MRI was performed <5w apart from the FBx in 423 patients, within 5-10 w in 261 and >10w in 122 patients. Adjusting for level of suspicion, previous biopsy result, age at MRI, race/ethnicity and marital status, the detection rates of any or CSC were not statistically different in any of the time intervals between the MRI/FBx (p[0.931 and p[0.538, respectively) . Furthermore, when analyzing time as a continuous variable (per week increase) there was no association between time from MRI to FBx and PCa detection (p[0.849 and p[0.666, respectively) .RESULTS: A total 1,181 lesions from 806 men were analyzed. Prostate cancer was detected in 34.5% (407) of lesions, with 21.4% (253), 13% (154) and 65.5% (774) of lesions detecting
